Please provide your email address to receive an email when new articles are posted on . Adding immune checkpoint inhibitors to neoadjuvant chemotherapy benefited certain patients with early-stage ...

Emerging growth opportunities in the next-generation immune checkpoint inhibitors market include the development of therapies targeting novel immune pathways employed to tackle cancer resistance ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver ...

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study. The findings ...

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...

Checkpoint inhibitor-based therapy and ISRT may replace autologous transplant and high-dose chemotherapy in low-risk relapsed cHL, reducing side effects while maintaining EFS outcomes. The CheckMate ...

Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project This retrospective study used ...

A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a ...

The medications most likely to cause thyroid eye disease are alemtuzumab, certain immune checkpoint inhibitors, amiodarone ...